Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

The development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among PLHIV. The meeting will focus on identifying opportunities for increased diagnosis and treatment of viral hepatitis in PLHIV, particularly in low and middle-income settings. Evidence that demonstrates the value of these curative therapies will be highlighted, encouraging stakeholders to discuss constructive solutions supporting equitable access to modern therapeutics while maintaining innovation. Learn the latest about viral hepatitis co-infection at the 3rd International HIV/Viral Hepatitis Co-Infection Meeting.

08:00
Registration
08:30
Welcome and Introduction
Wendy Spearman, University of Cape Town, South Africa
Slides
08:45
HBV-HIV Co-Infection: Epidemiology, Vaccine and Treatment Coverage
Mark Sonderup, University of Cape Town, South Africa
Slides
09:15
PMTCT for HBV
Monique Andersson, Stellenbosch University, South Africa
09:45
HBV Resistance and Escape Mutants
Anders Boyd, INSERM, France
Slides
10:15
Curing HBV: How Close Are We?
Patrick Kennedy, Barts and The London School of Medicine, United Kingdom
10:45
Panel Discussion
11:00
Refreshment Break and Poster Viewing — HBV epidemiology and outcomes
11:30
HCC Screening and Management
Patrick Kennedy, Barts and The London School of Medicine, United Kingdom
12:00
Children and Adolescents
Tammy Meyers, Chinese University of Hong Kong and University of the Witwatersrand, Hong Kong
Slides
12:30
Lunch and Poster Viewing — HCV epidemiology and natural history (12:30-13:00) — HCV testing monitoring and management (13:00-13:30)
13:30
HCV in PWID in Africa: A Hidden Epidemic
Niklas Luhmann, Médecins du Monde, France
Slides
13:50
Current Trends Worldwide: Implications for Elimination
Margaret Hellard, Burnet Institute, Australia
Slides
14:20
Role of Resistance and Resistance Testing for Managing HCV
Jürgen K. Rockstroh, University of Bonn, Germany
Slides
14:40
Is a Pan-Genotypic Therapy Ready for Prime Time?
Marina Klein, McGill University, Canada
Slides
15:00
Financing and the Scale Up of HCV Treatments: Entry of Generics
Sunil Suhas Solomon, Johns Hopkins University, United States
Slides
15:20
Medicines Patent Pool
Greg Perry, Medicines Patent Pool, Switzerland
Slides
15:30
Refreshment Break and Poster Viewing — HCV treatment access
16:00
Screening for Viral Hepatitis: Diagnostics (HBV and HCV)
Diana Hardie, University of Cape Town, South Africa
Slides
16:20
Screening for Viral Hepatitis: Liver Disease
Wendy Spearman, University of Cape Town, South Africa
Slides
16:40
WHO Diagnostic Guidelines
Philippa Easterbrook, WHO, Switzerland
17:00
Panel Discussion
17:15
Opening Overview and Community Perspective
Isabelle Andrieux-Meyer, Médecins Sans Frontières (MSF), Switzerland
Slides
17:25
Panel Discussion
Giten Khwairakpam, TREAT Asia, Thailand
Nelson Medeiros, OUT Wellbeing, South Africa
Andrew Scheibe, University of Cape Town, South Africa
Mark Sonderup, University of Cape Town, South Africa
Nalinikanta Rajkumar, Community Network for Empowerment (CoNE), India
18:15
Closing Remarks
Marina Klein, McGill University, Canada
Slides